BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $40

Benzinga · 10/14 15:10
BTIG analyst Sung Ji Nam maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $35 to $40.